GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Regent Pacific Group Ltd (OTCPK:RPGLF) » Definitions » EV-to-EBITDA

RPGLF (Regent Pacific Group) EV-to-EBITDA : -1.61 (As of Dec. 12, 2024)


View and export this data going back to . Start your Free Trial

What is Regent Pacific Group EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Regent Pacific Group's enterprise value is $12.28 Mil. Regent Pacific Group's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 was $-7.61 Mil. Therefore, Regent Pacific Group's EV-to-EBITDA for today is -1.61.

The historical rank and industry rank for Regent Pacific Group's EV-to-EBITDA or its related term are showing as below:

RPGLF' s EV-to-EBITDA Range Over the Past 10 Years
Min: -24.13   Med: -3.67   Max: 4.84
Current: -1.63

During the past 13 years, the highest EV-to-EBITDA of Regent Pacific Group was 4.84. The lowest was -24.13. And the median was -3.67.

RPGLF's EV-to-EBITDA is ranked worse than
100% of 718 companies
in the Drug Manufacturers industry
Industry Median: 14.19 vs RPGLF: -1.63

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-12-12), Regent Pacific Group's stock price is $0.0008. Regent Pacific Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was $-0.067. Therefore, Regent Pacific Group's PE Ratio (TTM) for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


Regent Pacific Group EV-to-EBITDA Historical Data

The historical data trend for Regent Pacific Group's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regent Pacific Group EV-to-EBITDA Chart

Regent Pacific Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.96 -14.82 4.84 -3.84 -2.19

Regent Pacific Group Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -3.84 - -2.19 -

Competitive Comparison of Regent Pacific Group's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Regent Pacific Group's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regent Pacific Group's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Regent Pacific Group's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Regent Pacific Group's EV-to-EBITDA falls into.



Regent Pacific Group EV-to-EBITDA Calculation

Regent Pacific Group's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=12.275/-7.607
=-1.61

Regent Pacific Group's current Enterprise Value is $12.28 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Regent Pacific Group's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 was $-7.61 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Regent Pacific Group  (OTCPK:RPGLF) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Regent Pacific Group's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.0008/-0.067
=At Loss

Regent Pacific Group's share price for today is $0.0008.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Regent Pacific Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was $-0.067.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


Regent Pacific Group EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Regent Pacific Group's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Regent Pacific Group Business Description

Traded in Other Exchanges
Address
5 Queen's Road Central, 8th Floor, Henley Building, Hong Kong, HKG
Regent Pacific Group Ltd is an investment holding company that runs through two segments: Biopharma and Corporate Investment. Its Biopharma segment is engaged in the research, development, manufacturing, marketing, and sales of pharmaceutical products, and it also develops artificial intelligence (AI) systems for the field of biological aging clocks. The Corporate Investment segment is engaged in the investment in listed and unlisted corporate entities. The majority of its revenue comes from the Biopharma segment. Its geographical segments are China, Europe, Hong Kong, and Taiwan.

Regent Pacific Group Headlines

No Headlines